Longboard Pharmaceuticals, Inc.
NASDAQ:LBPH
Overview | Financials
Company Name | Longboard Pharmaceuticals, Inc. |
Symbol | LBPH |
Currency | USD |
Price | 59.98 |
Market Cap | 2,341,960,906 |
Dividend Yield | 0% |
52-week-range | 59.98 - 59.98 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Kevin R. Lind |
Website | https://www.longboardpharma.com |
An error occurred while fetching data.
About Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD